Biotime Inc Sentiment Improves on Better Stock Potential

May 24, 2018 - By Marie Mckinney

BioTime, Inc. (NYSEAMERICAN:BTX) Logo

Sentiment for Biotime Inc (NYSEMKT:BTX)

Biotime Inc (NYSEMKT:BTX) institutional sentiment increased to 2.62 in Q4 2017. Its up 0.66, from 1.96 in 2017Q3. The ratio is better, as 55 hedge funds increased or started new positions, while 21 decreased and sold stock positions in Biotime Inc. The hedge funds in our partner’s database now hold: 57.90 million shares, up from 49.13 million shares in 2017Q3. Also, the number of hedge funds holding Biotime Inc in their top 10 positions was flat from 2 to 2 for the same number . Sold All: 5 Reduced: 16 Increased: 34 New Position: 21.

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies. The company has market cap of $285.46 million. The Company’s product candidates include Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV related facial lipoatrophy; OpRegen, which is in Phase I/IIa clinical trial for the treatment of the dry form of age-related macular degeneration; HyStem-BDNF, a preclinical development program for the delivery of recombinant human brain-derived neurotrophic factor directly into the stroke cavity of patients for aiding in tissue repair and functional recovery; and ReGlyde that is in preclinical development as a device for viscosupplementation and a combination product for drug delivery in osteoarthritis. It currently has negative earnings. The firm also develops AST-OPC1, a therapy derived from pluripotent stem cells that is in a Phase I/IIa clinical trial for spinal cord injuries; AST-VAC1, a patient-specific cancer immunotherapy that is in Phase II clinical trial for acute myeloid leukemia; and AST-VAC2, a non-patient specific cancer immunotherapy, which is in Phase I/IIa clinical trial to treat non-small cell lung cancer.

The stock decreased 2.17% or $0.05 during the last trading session, reaching $2.25. About 193,294 shares traded. BioTime, Inc. (NYSEMKT:BTX) has declined 25.77% since May 24, 2017 and is downtrending. It has underperformed by 37.32% the S&P500.

Analysts await BioTime, Inc. (NYSEAMERICAN:BTX) to report earnings on August, 1. They expect $-0.08 EPS, down 60.00 % or $0.03 from last year’s $-0.05 per share. After $-0.09 actual EPS reported by BioTime, Inc. for the previous quarter, Wall Street now forecasts -11.11 % EPS growth.

Broadwood Capital Inc holds 8.98% of its portfolio in BioTime, Inc. for 29.97 million shares. Manatuck Hill Partners Llc owns 351,822 shares or 0.39% of their US portfolio. Moreover, Dafna Capital Management Llc has 0.32% invested in the company for 275,000 shares. The Florida-based Prescott General Partners Llc has invested 0.17% in the stock. Berson & Corrado Investment Advisors Llc, a New York-based fund reported 74,875 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.